Abstract
Coronavirus disease 2019 (COVID-19) has infected people all over the world. While scientists are busy finding a vaccine and medicine, it becomes difficult to control the spread and manage patients. Mathematical models help one get a better feel for the challenges in patient management. With this in mind, our team developed a model called Multilevel Integrated Model with a Novel Systems Approach (MIMANSA) Welling et. al (2020). MIMANSA is a multi-parametric model. One of the challenges in the design of MIMANSA was to simulate the incubation period of coronavirus. The incubation period decides when virus-infected patients would show symptoms. The probability distribution function (PDF), when applied to the number of virus-infected cases, gives a good representation of the process of the incubation period. The probability distribution functions can take various forms. In this paper, we explore a variety of PDFs and their impact on parameter estimation in the MIMANSA model. For our experiments, we used Weibull, Gaussian, uniform, and Gamma distribution. To ensure a fair comparison of Weibull, Gaussian, and Gamma distribution, we matched the peak value of the distribution. Our results show that the Weibull distribution with shape 7.7 and scale 7 for 14 days gives a better training model and predictions.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
None
Funding Statement
Pi Innovate, Pune, India
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not required
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.